Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations.

Lung cancer (Amsterdam, Netherlands) - 1 Jun 2011

Wu Shang-Gin, Yang Chih-Hsin, Yu Chong-Jen, Lee Jih-Hsiang, Hsu Ya-Chieh, Chang Yih-Leong, Shih Jin-Yuan, Yang Pan-Chyr

Abstract excerpt

There are no reports about epidermal growth factor receptor (EGFR) mutations and the responsiveness to pemetrexed treatment. In order to understand the influence of EGFR mutations on pemetrexed response, we performed EGFR sequencing of lung adenocarcinoma from patients undergoing pemetrexed treatment and analyzed their response to pemetrexed. The pemetrexed-treated lung adenocarcinoma patients with adequate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutamates

Share to Green Fluorescent Proteins

Share to Guanine

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Pemetrexed

Source

Identifiers

PMID: 21111508
DOI: 10.1016/j.lungcan.2010.10.012

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations.PMID 21111508Read ↗

Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed.Semantic proximity Read ↗

Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes.Semantic proximity Read ↗

Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.Semantic proximity Read ↗

Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI).Semantic proximity Read ↗

Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.Semantic proximity Read ↗

EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Nonsquamous Nonsmall Cell Lung Cancer.Semantic proximity Read ↗

Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R.Semantic proximity Read ↗

Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma.Semantic proximity Read ↗

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.Semantic proximity Read ↗

Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.Semantic proximity Read ↗

[Effects of EGFR-TKIs on sequential pemetrexed for advanced pulmonary adenocarcinoma].Semantic proximity Read ↗

Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.